Pancreatic Cancer Research

ResearcherUniversity of AlabamaActive in the last 2 years

Jeremy B. Foote

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6621-6096; OpenAlex author ID A5013409342. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 4 papers

Papers 9

  1. Variable efficacy of the non-covalent KRAS G12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer. Last author DOI 10.1038/s41698-026-01493-z↗
  2. Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. Co-author DOI 10.1172/jci.insight.198489↗
  3. ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment Co-author DOI 10.64898/2026.01.15.699725↗
  4. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.02.11.705411↗
  5. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  6. Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41417-025-00967-9↗
  7. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  8. Breaking the stromal barrier in pancreatic cancer: Advances and challenges. First author DOI 10.1016/j.bbcan.2023.189065↗
  9. Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges. Co-author DOI 10.1016/j.semcancer.2023.11.002↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ganji Purnachandra Nagaraju · 8 shared papers, 2023–2026 · strength 1.96
  2. Sujith Sarvesh · 7 shared papers, 2025–2026 · strength 1.69
  3. Dhana Sekhar Reddy Bandi · 6 shared papers, 2025–2026 · strength 1.41
  4. Bassel F. El‐Rayes · 6 shared papers, 2025–2026 · strength 1.41
  5. Mehmet Akce · 5 shared papers, 2025–2026 · strength 1.14
  6. Julienne L. Carstens · 3 shared papers, 2025–2026 · strength 0.66
  7. Karina Jin Yoon · 3 shared papers, 2025–2026 · strength 0.65
  8. Ashiq Masood · 2 shared papers, 2025–2026 · strength 0.46
  9. Yulia Y. Maxuitenko · 2 shared papers, 2025–2026 · strength 0.41
  10. Donald J Buchsbaum · 2 shared papers, 2025–2026 · strength 0.41
  11. Adam B. Keeton · 2 shared papers, 2025–2026 · strength 0.41
  12. Gary Anthony Piazza · 2 shared papers, 2025–2026 · strength 0.41
  13. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.41
  14. Upender Manne · 2 shared papers, 2025 · strength 0.38
  15. Mohana Chakkera · 1 shared paper, 2024 · strength 0.31
  16. Batoul Farran · 1 shared paper, 2024 · strength 0.31
  17. Christopher Klug · 1 shared paper, 2026 · strength 0.28
  18. Harrison Kim · 1 shared paper, 2026 · strength 0.27
  19. Midhun Malla · 1 shared paper, 2026 · strength 0.27
  20. Zhi-Ren Liu · 1 shared paper, 2026 · strength 0.27
  21. Mundla Srilatha · 1 shared paper, 2023 · strength 0.24
  22. Rama Rao Malla · 1 shared paper, 2023 · strength 0.24
  23. Yuvasri Golivi · 1 shared paper, 2025 · strength 0.19
  24. Cameron J. Herting · 1 shared paper, 2025 · strength 0.19
  25. Olatunji Boladale Alese · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.